Physiologic and pathologic functions of the NPP nucleotide pyrophosphatase/phosphodiesterase family focusing on NPP1 in calcification by Terkeltaub, Robert
Review
Physiologic and pathologic functions of the NPP nucleotide pyrophosphatase/
phosphodiesterase family focusing on NPP1 in calcification
Robert Terkeltaub
University of California School of Medicine, VA Medical Center, 3350 La Jolla Village Drive, San Diego,
CA, USA
Received 1 November 2005; accepted in revised form 14 November 2005; Published online 1 June 2006
Key words: ANK, ANKH, cartilage, inorganic phosphate, inorganic pyrophosphate, osteopontin
Abstract
The catabolism of ATP and other nucleotides participates partly in the important function of nucleotide salvage by
activated cells and also in removal or de novo generation of compounds including ATP, ADP, and adenosine that
stimulate purinergic signaling. Seven nucleotide pyrophosphatase/phosphodiesterase NPP family members have been
identified to date. These isoenzymes, related by up conservation of catalytic domains and certain other modular domains,
exert generally non-redundant functions via distinctions in substrates and/or cellular localization. But they share the
capacity to hydrolyze phosphodiester or pyrophosphate bonds, though generally acting on distinct substrates that include
nucleoside triphosphates, lysophospholipids and choline phosphate esters. PPi generation from nucleoside triphosphates,
catalyzed by NPP1 in tissues including cartilage, bone, and artery media smooth muscle cells, supports normal tissue
extracellular PPi levels. Balance in PPi generation relative to PPi degradation by pyrophosphatases holds extracellular PPi
levels in check. Moreover, physiologic levels of extracellular PPi suppress hydroxyapatite crystal growth, but
concurrently providing a reservoir for generation of pro-mineralizing Pi. Extracellular PPi levels must be supported by
cells in mineralization-competent tissues to prevent pathologic calcification. This support mechanism becomes
dysregulated in aging cartilage, where extracellular PPi excess, mediated in part by upregulated NPP1 expression
stimulates calcification. PPi generated by NPP1modulates not only hydroxyapatite crystal growth but also chondrogenesis
and expression of the mineralization regulator osteopontin. This review pays particular attention to the role of NPP1-
catalyzed PPi generation in the pathogenesis of certain disorders associated with pathologic calcification.
Abbreviations: ANK –protein product of the murine ankylosis disease susceptibility gene; CPPD–calcium pyrophosphate
dihydrate; CILP–cartilage intermediate layer protein; HA–hydroxyapatite; IIAC–Idiopathic Infantile Artery Calcification;
MV–matrix vesicles; NPP–nucleotide pyrophosphatase/phosphodiesterase; OPLL–ossification of the posterior longitu-
dinal ligament; SMC–smooth muscle cells; SNP–single nucleotide polymorphism; TNAP–tissue nonspecific alkaline
phosphatase
Introduction
The extracellular catabolism of ATP and other nucleotides
by coordinated ecto-enzymes mediates nucleotide salvage
by activated cells and also drives removal or de novo gene-
ration of compounds including ATP, ADP, and adenosine
that stimulate purinergic signaling [1Y3]. This subject is
reviewed in depth by Stefan et al. in this special issue of the
journal. Among the many enzymes participating in nucleo-
tide catabolism are certain nucleotide pyrophosphatase/phos-
phodiesterase (NPP) family members, including NPP1, the
principal subject of this review. Seven NPPs have been
identified to date (Figure 1)[ 4]. These isoenzymes, related
by 24%Y60% conservation in catalytic domains [4] and by
conservation of certain other modular domains, exert
generally non-redundant functions via distinctions in
substrates and/or subcellular localization. For example,
the type II transmembrane ecto-enzymes NPP1 (PC-1,
npps) and NPP3 (B10, CD203c, PD-1, gp130
RB13-6),
which exist as disulfide-bonded homodimers in mem-
branes, and whose extracellular domains can be proteolyt-
ically liberated into secreted forms, exert nucleoside
triphosphate pyrophosphohydrolase (NTPPPH) activity
that generates PPi from ATP and other nucleoside
triphosphates, as discussed below, NPP1 and NPP3 both
subserve other functions by alkaline pH optimum nucleo-
tide phosphodiesterase activities [5Y8]. However, the
dileucine motif in the cytosolic tail of NPP1 (but not
NPP3) mediates differential subcellular localization to the
basolateral and apical plasma membrane, respectively, in
polarized cell types [5].
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and NPP3 in structural organization (Figure 1), is synthe-
sized as a pro-enzyme and further processed to be a
secretory molecule (4.9). NPP2 lysophospholipase D
specific activity is much higher than that of other NPP
family members and specific activity as a nucleotide
pyrophosphatase/phosphodiesterase much lower than that
of NPP1 and NPP3 [10, 11]. Correspondingly, we have
observed that direct expression of NPP2 did not increase
extracellular PPi in chondrocytes, under conditions in
which NPP2 did stimulate both alkaline phosphatase and
increased calcification [12]. NPP6 and the intestinal
enzyme NPP7 (Figure 1) exert lysophospholipase C or
choline phosphate esterase activities [4]. The secretion of
NPP2 by multiple tissues, and NPP2 accumulation in
extracellular fluids, allows NPP2, in large part via lysophos-
pholipase D activity, to exert a variety of biologically
significant effects on cell growth, differentiation, adhesion,
and migration, translated into functional effects in angio-
genesis, tumor metastasis, and embryonic development
[4, 13Y15].
Comparative molecular structure-function of NPPs and
their substrate specificities were recently reviewed in a
thorough and lucid manner [4]. This review focuses on the
functions of NPP1 in the regulation of physiologic and
pathologic calcification, principally via PPi generation
from nucleoside triphosphates in tissues (and cells)
including cartilage (and chondrocytes), bone (and osteo-
blasts), and large arteries (and smooth muscle cells
(SMCs)).
NPP1 and ANK in PPi metabolism and calcification
Subcellular trafficking mediated by the dileucine motif in
the NPP1 (but not NPP3) cytosolic tail accounts for the
observation that the majority of NPP activity in osteoblast
plasma membranes and plasma membrane-derived miner-
alizing secretory vesicles (termed matrix vesicles) is
accounted for by NPP1 [17]. Concordantly, cultured
osteoblasts of NPP1 null mice demonstrate marked
depletion (of up to 50%) in extracellular PPi [18].
PPi potently inhibits the nucleation and propagation of
hydroxyapatite (HA) and other basic calcium phosphate
crystals [19]. As such, maintenance of physiologic extra-
cellular PPi levels by mineralization-competent cells
suppresses spontaneous calcification. This has been strik-
ingly illustrated in certain mouse models of deficient
NPP1-catalyzed PPi generation [18, 20, 21], or alternately,
ANK-mediated PPi transport [18, 22]. In humans, 18 of 23
kindreds demonstrated homozygosity or compound hetero-
zygosity for mutations of NPP1 in association with
generalized arterial calcification of infancy (GACI, IIAC,
MIM# 208000) [23, 24]. This entity, described in approx-
imately 180 individuals to date, is characterized by large
artery media calcification and myointimal proliferation,
commonly associated with periarticular calcification
[23Y25]. The disease is frequently lethal but may respond
to treatment with bisphosphonates, which function in part
as non-hydrolyzeable PPi analogues [25]. GACI is linked
to systemic (blood, urine, tissue) extracellular PPi defi-
ciency [25, 26] discovered by us to be caused by mutations
Figure 1. General Structural Features of NPP family members. The schematic highlights related structural features of NPPs 1Y7, as discussed further in
the text.
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Many of these NPP1 mutations, which are mostly in the
nuclease-like and catalytic, domains, but also reported in
the somatomedin B-like domain, have been established to
impair NPP1 catalytic activity [23, 24].
Notably, PPi serves as reservoir for alkaline phospha-
tase-catalyzed Pi generation that is pro-mineralizing, as
illustrated by osteopenia in long bones of NPP1 deficient
mice [27, 28]. As such, PPi generation can both suppress
and promote HA crystal deposition, depending on relative
tissue levels of NPP1 and alkaline phosphatase (Figure 2)
[16Y21, 27, 28]. The capacity of chondrocytes to produce
copious extracellular PPi is particularly double edged, as it
is directly promotes calcium pyrophosphate dihydrate
(CPPD) crystal deposition (Figure 2). Depending on
cartilage ATP and PPi concentrations, and the level of
activity of Pi-generating ATPases and pyrophosphatases,
NPP1 excess promotes both HA and CPPD crystal
formation by articular chondrocytes [12, 29Y31], an event
that commonly occurs in the joint in human aging and
osteoarthritis (OA) [32].
PPi appears to directly regulate expression of certain
genes (including inductive effects first described by us for
osteopontin and MMP-13 expression and suppressive
effects on Sox9 expression)[18, 33Y35]. PPi regulates
certain cellular differentiation and functions including
protein synthesis [19], chondrogenesis [35], and pro-
mineralizing chondrocyte maturation to terminal hyper-
tophic differentiation transduced partly by Pit-1 mediated
Pi uptake [36]. Such effects of PPi are analogous to effects
of not only Pi [37, 38] but also bisphosphonate PPi
analogues [39, 40]. It is not clear in which subcellular
compartments PPi could act to carry out these effects and
what contributions Pi derived from PPi makes in these
activities of PPi.
Mammalian extramitochondrial mechanisms for PPi
production, degradation, and transport were recently
reviewed in depth [19]. In cells such as osteoblasts and
chondrocytes that normally express NPP1 relatively ro-
bustly, NPP1 and NPP3 increase intracellular PPi, sus-
pected to be in large part in the lumen of the ER and Golgi
[12, 16, 31]. Critical to support of extracellular PPi is
apparent direct PPi transport by the multiple-pass trans-
membrane protein ANK [41], which makes a major
contribution to moving to the movement into the extracel-
lular space of intracellular PPi, including the fraction of
intracellular PPi generated by NPP1 [34].
NPP1 and PPi metabolism in cartilage and bone
Extracellular PPi rises markedly in articular cartilage in
direct association with aging and OA, and resultant matrix
supersaturation with PPi and cartilage matrix abnormalities
that alter the solubility product of PPi and Ca
2+ promote
calcification [42]. Physiologic chondrocyte PPi metabolism
is regulated in part by growth factor and cytokine
regulatory effects on chondrocyte NPP1 expression. Inter-
ruption in regulatory checks and balances on articular
cartilage PPi metabolism appears to occur in aging and
diseases including OA. For example, the chondrocyte
growth factor TGF induces both NPP1 expression and
elevation of extracellular PPi [12, 31, 43]. The capacity of
TGF to increase cartilage NPP activity and extracellular
PPi levels directly correlates with donor age [12, 31, 44].
The TGF-stimulated cellular program for chondrocyte
Figure 2. Proposed NPP1-mediated and PPi-dependent mechanisms
stimulating CPPD and HA crystal deposition in aging and osteoarthritis
(OA): Roles of ATP and PPi Metabolism and inorganic phosphate (Pi)
generation in pathologic cartilage calcification. This model presents
mechanisms underlying the common association of extracellular PPi
excess with both CPPD and HA crystal deposition in OA and
chondrocalcinosis cartilages, as well as the paradoxical association of
extracellular PPi deficiency (from defective ANK or PC-1/NPP1 expres-
sion) with pathologic calcification of articular cartilage with HA crystals
in vivo. Factors driving pathologic calcification are indicated in green and
physiologic factors suppressing calcification in red. Excess PPi generation
in aging cartilages in idiopathic CPPD deposition disease of aging, and in
OA cartilages, is mediated in part by marked increases in NTPPPH
activity, mediated in large part by the PC-1/NPP1 isoenzyme. In
idiopathic chondrocalcinosis of aging and in OA, there are substantial
increases in joint fluid PPi derived largely from cartilage. NPP1 not only
directly induces elevated PPi but also matrix calcification by chondrocytes
in vitro. Depending on extracellular availability of substrate PPi and the
activity of pyrophosphatases, the availability of substrate ATP and the
activity of ATPases, and other factors such as substantial local Mg
++
concentrations, HA crystal deposition, as opposed to CPPD deposition,
may be stimulated. In this model, excess extracellular PPi also may result
from heightened release of intracellular PPi via increased ANK expression
in OA and abnormal ANK function in familial chondrocalcinosis, as well
as from deficient activity of pyrophosphatases (such as TNAP and
possibly inorganic pyrophosphatase) in certain primary metabolic disor-
ders. Also illustrated at the top of this schematic is the role in cartilage
calcification in OA and aging of altered TGF expression and respon-
siveness, which drives PPi generation and release mediated via NPP1 and
ANK, and diminished responsiveness to IGF-I, which normally suppresses
elevation of chondrocyte extracellular PPi.
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ATP generation [45] and stimulation of NPP1 movement to
the plasma membrane [12, 31].
Osteoblasts and chondrocytes have particularly high
levels of both NPP1 expression and NPP specific activity
[19, 46, 47]. Moreover, chondrocyte NPP activity increases
in direct condordance with cartilage PPi generation (to an
average of double normal levels) in a donor age-dependent
manner [47]. The age-dependent increases in NPP activity
are directly linked to CPPD crystal deposition disease [47].
Upregulation of NPP1 but not NPP3 is associated with
calcification by chondrocytic cells in situ and in vitro [12,
31]. Unlike NPP1, which regulates both intracellular and
extracellular PPi in chondrocytes, NPP3 appears to princi-
pally regulate only intracellular PPi [12, 31].
Chondrocyte mitochondrial dysfunction associated with
spontaneous OA in Hartley guinea pig knees promotes
ATP depletion [48]. Significantly increased NPP activity
and extracellular PPi develop concurrent with the ATP-
depleted state [48]. Hence, increased ATP-scavenging by
energy-depleted chondrocytes likely promotes extracellular
PPi excess in human OA and aging cartilages.
A series of studies from one research group errone-
ously reported that cartilage intermediate layer protein
(CILP), an interterritorial and pericellular matrix constit-
uent in cartilage with a molecular weight similar to that
of NPP1, was an NPP family member, even though
there was no structural similarity of CILP to NPP family
members [49Y51]. We refuted this work [52], and in so
doing, we demonstrated that increased expression of one
of 2 CILP isoforms (CILP-1) in aging cartilage interferes
with the regulatory effects of IGF-I on PPi metabolism,
thereby promoting increased extracellular PPi and cartilage
calcification.
NPP1 and PPi metabolism in pathologic soft tissue
calcification syndromes and pivotal role of
osteopontin depletion
Consistent with the apparent co-dependent function of
ANK and NPP1 to raise extracellular PPi [34] is the
remarkable similarity in the consequences of deficient
ANK and PC-1 function in vivo. Both NPP1 deficient mice
and mice homozygous for a natural C-terminal ANK
mutant that appears to incapacitate ANK PPi transport
function (ank/ank mice) spontaneously develop a progres-
sive phenotype of pathologic soft tissue calcification that
with increasing age comes to include perispinal ligament
hyperostosis, periarticular calcification leading to ossific
fusion of peripheral joints, extensive articular cartilage
degeneration associated with HA deposits, and large artery
calcification [22, 35]. The initial implication of NPP1
deficiency in spontaneous pathologic soft tissue calcifica-
tion was in Ftiptoe walking_ ttw/ttw mice, which are
homozygous for a spontaneous nonsense mutation that
encodes for a stop codon at tyrosine 568, a position 30 of
the NPP1 catalytic site [20]. It is not yet known if NPP1
expression is depressed or absent in ttw/ttw mice, or if the
ttw mutation, like many of the NPP1 mutations seen in
humans with GACI, critically impairs catalytic activity,
putatively by interfering with substrate binding.
Human ossification of the posterior longitudinal liga-
ment (OPLL), a form of spontaneous pathologic perispi-
nal ligament calcification common in Japanese subjects,
has been linked with certain SNPs in the NPP1 gene
[53Y55]. It will be of interest to see if the implicated NPP1
sequence variants affect NPP1 expression and function.
Interestingly, the inflammatory cytokine IL-1 depresses
NPP1 expression, NPP activity, and extracellular PPi in
chondrocytes [43]. In this context, a õ30% depression in
serum NPP activity is seen in males with the chronic
inflammatory disease ankylosing spondylitis [56], a condi-
tion that, like OPLL and spinal alterations in NPP1-
deficient mice, associated with ankylosing intervertebral
soft tissue calcification.
Interestingly, periarticular and bone abnormalities are far
more substantial and progressive in NPP1-deficient mice
than in NPP1-deficient humans with GACI. Conversely
NPP1 deficient mice [35] do not demonstrate the severe
myointimal proliferative changes seen in arteries in human
GACI [24, 25]. We speculate that the relatively high level
of normal serum Pi in mice compared to humans (e8 vs.
e4.5 mg/dL, respectively) [46] plays a major role in
determining these phenotypic distinctions. In this context,
high dietary Pi worsens pathologic calcification in NPP1
null mice [46]. Conversely, low serum Pi induced by
crossbreeding with PHEX null mice is associated with
correction of pathologic artery and soft tissue calcification
in both NPP1 null and ank/ank mice [46].
Unlike cultured cells of ank/ank mice, NPP1-deficient
cells demonstrate low intracellular as well as extracellular
PPi levels [18]. Thus, the common basis for the remarkably
similar hypermineralizing phenotypes seen in ank/ank mice
and in NPP1 null mice (and the pathologic calcification
seen in the human NPP1 deficiency state GACI) appears to
rest in depression of extracellular PPi. Furthermore, the
marked depletion of extracellular PPi and of osteopontin,
the rapid, extensive calcification by both NPP1j/j and
ank/ank osteoblasts in culture are corrected by soluble
NPP1, reinforcing a central role of NPP1 in skeletal PPi
and Pi metabolism and osteopontin expression [18], a
notion strongly supported by in vivo studies [21, 33].
Pi, mediated by uptake through plasma membrane
sodium-phosphate co-transport, stimulates expression of
osteopontin, an inhibitor of HA crystal growth and
promoter of mineral resorption [37, 38]. As cited above,
exogenous PPi also induces osteopontin expression [18,
33]. It is not yet clear whether uptake of Pi derived from
extracellular PPi is a major signaling intermediate in this
process. Nevertheless, it is remarkable that one HA crystal
growth inhibitor (PPi) promotes expression of a second in
the form of osteopontin. Because osteopontin knockout
mice have relatively mild changes in mineralization in
contrast to the marked phenotypic abnormalities in extra-
cellular PPi-deficient mice, PPi clearly higher than osteo-
pontin in the physiologic hierarachy of HA crystal growth
inhibitors.
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role in regulating nucleation of mineral in chondrocyte-,
osteoblast-, and apparently artery smooth muscle cell-
derived secretory bodies released by budding from the
plasma membrane and termed matrix vesicles (MVs). The
MVs, are enriched in NPP1 and TNAP, whose catalytic
domains are predominantly exposed at the external face of
MVs. The MVs provide a sheltered environment for
initiation of mineral crystal formation in a manner
modulated by the concentration of PPi, though mineral
propagation is mediated by other factors, including
availability of fibrillar collagen in Fosteoid_ to serve as a
nidus for calcification with HA [46]. NPP1 is clearly the
principal NPP associated with chondrocyte-derived and
osteoblast-derived MVs [16, 17, 21, 30, 57]. NPP1 and
TNAP exert mutually antagonistic regulatory effects on
crystal deposition in MVs, and activity not shared by NPP3
[16]. Cell differentiation and a variety of calciotropic
hormones and cytokines (including 1,25 dihydroxyvitamin
D3, TGF, and IL-1) can regulate the NPP1 content, NPP
and alkaline phosphatase activities, PPi content, and other
compositional features of MVs [29]. However, we have not
seen concentrated ANK localization in MVs [33], likely
contributing to the observation that correction of patholog-
ic calcification by TNAP deficiency is less marked in ank/
ank than NPP1j/j mice [33].
NPP1 and PPi deficiency states are linked to accelerated
chondrogenesis
Taken together, it is clear that NPP1 and PPi physiologi-
cally function to prevent calcification of arteries and
certain other soft tissues at the level of cell differentiation,
and not simply at the level of mineral formation and
resorption in the extracellular matrix. Most strikingly, we
recently discovered that trans-differentiation of artery
SMCs and accelerated intra-arterial chondrogenic differen-
tiation mediated directly by PPi depletion promotes
spontaneous artery media calcification in NPP1j/j and
ank/ank mice [35]. Specifically, we observed that NPP1
deficiency promoted the spontaneous emergence of chon-
drogenesis from bone marrow stromal cells under non-
calcifying conditions. Cultured NPP1j/j aortic SMC
preparations and NPP1j/j aortic cells 023060 in situ
expressed cbfa1, osteocalcin, and chondrocyte-specific
collagens. Osteopontin expression was depressed and pro-
calcifying alkaline phosphatase specific activity and calci-
fication were markedly upregulated in cultured NPP1j/j
SMCs [35]. In contrast, there was no gross alteration in
expression of the physiologic artery calcification inhibitors
matrix gla protein and osteoprotegerin in NPP1j/j mouse
arterial cells [35]. The capacity of exogenous PPi to correct
spontaneous chondrogenesis in NPP1j/j bone marrow
stromal cells under non-calcifying conditions suggested
that extracellular PPi deficiency directly promoted chon-
drogenesis and trans-differentiation to chondrocytes of the
SMCs, a notion supported by aortic media calcification and
changes in cultured SMC differentiation and calcification
in ank/ank mice [35]. Therefore, acquired regional and
systemic decrements in NPP1 and ANK expression and
extracellular PPi could contribute to intra-arterial chondro-
osseous metaplasia and calcification in aging, diabetes
mellitus, and atherosclerosis. In addition, it is noteworthy
that systemic PPi deficiency is seen in hemodialysis-
dependent renal insufficiency, a condition associated with
hyperphosphatemia and often extensive artery media and
periarticular calcifications [58].
Conclusions and perspectives
Support of extracellular PPi levels by NPP1 and ANK
inhibits pathologic soft tissue calcification but supports
hard tissue mineralization in long bones and promotes
calcification of articular cartilages in aging and OA. PPi is
a central regulator of calcification in the extracellular
matrix, but extracellular PPi regulates gene expression and
cellular differentiation, including major physiologic effects
on chondrogenesis and expression of osteopontin. The
larger significance of mutants of NPP1 and ANK in disease
continues to be elucidated. For example, mutants of
ANKH, concentrated mainly at the N-terminal end of the
molecule, have been linked with both autosomal dominant
familial and Fsporadic_ CPPD crystal deposition disease of
articular cartilage [59, 60]. But other ANKH mutants
clustered in putative cytosolic loops well-removed the N-
and C-termini are linked with the distinct phenotype of
craniometaphyseal dysplasia, a disease mediated by abnor-
mal skeletal remodeling more than pathologic calcification
[61, 62]. Polymorphisms in the human homologue of ANK
(ANKH) also appear to contribute to differences in hand
bone size and geometry that may influence bone fragility in
a homogeneous Chuvasha population [63]. In the same
population, NPP1 gene polymorphisms appeared to con-
tribute to variance in severity of hand joint OA [64].
NPP1, in a catalytic activity-independent manner, in-
hibits ligand-induced insulin receptor signaling [65], an
effect that appears linked to NPP1 mutations associated
with type II diabetes mellitus in some but not all ethnic
groups studied [66, 67]. Interestingly, the K173Q SNP of
NPP1, which maps to the second somatomedin-B-like
domain of NPP1 and has been linked to insulin resistance,
does not modulate NPP1 dimerization or catalytic activity
or affect physical interaction of NPP1 with the insulin
receptor [68]. Inherited states of putative Fgain-of-function_
of NPP1 also have been linked to obesity [69], also likely
mediated primarily via effects on insulin receptor signal-
ing. However, it is not likely that the numerous NPP1
catalytic site-independent mutants implicated as interfering
with ligand-induced insulin receptor signaling directly
affect mineralization.
Last, NPP1 not only generates PPi but also modulates N-
glycosylation and secretion of glycoproteins, and proteo-
glycans sulfation [6Y8], and NPP1 also scavenges ATP and
thereby regulates purinergic receptor signaling. The poten-
tial roles in calcification of these alternative effects of
NPP1, and of other NPP1 interactions with nucleotide-
NPP1 in calcification 375hydrolyzing ecto-ezymes, remain to be determined. Nev-
ertheless, the remarkable phenotypic similarities between
NPP1-deficient and ANK-deficient mice strongly support
the central role of NPP1 catalyzed PPi generation in the
regulation of calcification.
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